NCT03179904
Breast Cancer Type: HER2+
Hormone Mutations: ER+, PR+
Other Mutations:
Breast Cancer Tissue:
Recruitment Status: Recruiting
Phase 2
Drug Category: Therapeutic Antibody, Misc Inhibitor, Chemotherapy
Key Eligibility Criteria:
Gender: All
Age: 18 Years and older (Adult), Senior)
Location of Metastases:
Additional Notes:
Exclusions: Patients with leptomeningeal disease or uncontrolled brain metastasis
https://ClinicalTrials.gov/show/NCT03179904